Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor

Table 1 Tumor mass on the 11th day and TIR of the five groups (n = 6, mean ± SD)

Group	Tumor mass (g)	TIR (%)
ACM	1.06 ± 0.27a	22.63
High dosage of MPNS-ACM	0.65 ± 0.26aceg	52.55
Low dosage of MPNS-ACM	0.95 ± 0.15ag	30.66
MPNS	1.23 ± 0.25	10.22
Control	1.37 ± 0.21	//

^aP < 0.05 vs control group;

^cP < 0.05 vs ACM group;

^eP < 0.05 vs group of low dosage MPNS-ACM;

^gP < 0.05 vs MPNS group.

Table 2 White blood cells, marrow CFU-GM, serum ALT and creatine(n = 6, mean ± SD)

Group	White blood cells (×109/L)	CFU-GM number (/104)	ALT (U/L)	Creatine (μmol/L)
ACM	76.67 ± 17.32	74.75 ± 21.91b	30.67 ± 16.51	12.17 ± 1.17
High dosage of MPNS-ACM	70.00 ± 8.74	107.83 ± 14.75	29.17 ± 14.36	12.50 ± 1.05
Low dosage of MPNS-ACM	74.67 ± 9.71	115.25 ± 12.53	23.83 ± 3.55	13.00 ± 2.19
MPNS	79.00 ± 11.23	117.50 ± 12.75	20.83 ± 4.71	12.00 ± 1.55
Control	74.83 ± 6.08	117.00 ± 12.48	37.83 ± 35.13	12.67 ± 1.51

^bP < 0.001 vs control group.

Table 3 Inhibition concentration of the drugs (µg/mL)

Group	IC10	IC50	IC90
ACM	0.006	0.09	1.53
MPNS	10.34	97.8	925
MPNS-ACM	0.19	1.07	6.03